Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan

Published:2023-09-19 Issue:12 Volume:58 Page:1188-1197
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Morimoto Kosuke^ORCID,Moriwaki Kensuke,Shimozuma Kojiro,Nakayama Takeo

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00535-023-02041-3.pdf

Reference26 articles.

1. Cancer Statistics’22. National Cancer Center. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2022.pdf. Accessed 28 Nov 2022

2. Cancer Information Service, National Cancer Center, Japan. Annual survival report of hospital-based cancer registries. https://hbcr-survival.ganjoho.jp/. Accessed 28 Nov 2022

3. Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980–2018. JAMA Netw Open. 2021;4: e2118457.

4. Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. Japan: Kinbara Publishing Co., Ltd; 2021.

5. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China;Frontiers in Pharmacology;2024-09-04

2. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group;Japanese Journal of Clinical Oncology;2024-08-24

3. Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2024-07-12

4. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China;Expert Review of Pharmacoeconomics & Outcomes Research;2024-04-11